Cargando…

2438. Positive Cerebrospinal Fluid Cultures from Intraventricular Reservoirs for CLN2 Patients: One Institution's Experience

BACKGROUND: Enzyme replacement therapy (ERT) with cerliponase alfa (Brineura) has been shown to slow progression of milestone deterioration in Neuronal Ceroid Lipofuscinosis Type 2 (CLN2), an inherited neurodegenerative lysosomal storage disorder. Brineura must be administered intraventricularly eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Fote, Gianna, Schafenacker, Amanda, Sherlock, Daniel C, So, Justin, Himstead, Alexander, Davies, Jordan, Pedroza, Sarah, Gornick, Wendi, Wang, Raymond, Olaya, Joffre, Arrieta, Antonio C, Singh, Jasjit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677598/
http://dx.doi.org/10.1093/ofid/ofad500.2057
_version_ 1785150167533486080
author Fote, Gianna
Schafenacker, Amanda
Sherlock, Daniel C
So, Justin
Himstead, Alexander
Davies, Jordan
Pedroza, Sarah
Gornick, Wendi
Wang, Raymond
Olaya, Joffre
Arrieta, Antonio C
Singh, Jasjit
author_facet Fote, Gianna
Schafenacker, Amanda
Sherlock, Daniel C
So, Justin
Himstead, Alexander
Davies, Jordan
Pedroza, Sarah
Gornick, Wendi
Wang, Raymond
Olaya, Joffre
Arrieta, Antonio C
Singh, Jasjit
author_sort Fote, Gianna
collection PubMed
description BACKGROUND: Enzyme replacement therapy (ERT) with cerliponase alfa (Brineura) has been shown to slow progression of milestone deterioration in Neuronal Ceroid Lipofuscinosis Type 2 (CLN2), an inherited neurodegenerative lysosomal storage disorder. Brineura must be administered intraventricularly every 2 weeks, necessitating the placement of ventricular reservoirs and requiring frequent access. Traditionally, positive cerebrospinal fluid (CSF) cultures are managed with device replacement and antibiotic treatment. We sought to establish which circumstances might allow for careful observation without device removal. In this study, we report our single-institution experience with clinical outcomes of positive CSF cultures in 16 CLN2 patients over 6 years. METHODS: We retrospectively reviewed a cohort of 16 patients with CLN2 disease who had ventricular reservoirs placed for ERT administration. At each ERT infusion, CSF was collected by sterile technique and cultured by both thioglycolate broth and agar plate. Epidemiologic and microbiologic data, symptomatology, total antibiotic days, removal and replacement of ventricular reservoir, hospital length of stay, and mortality were analyzed for each patient. RESULTS: In our cohort, 11 of 16 patients (69%) had at least one positive CSF culture (Fig 1). Of the 11 with positive cultures, only 3 had their device removed and replaced for a positive culture with concurrent antibiotic treatment at our center, and 2 patients subsequently have been treated with prophylactic antibiotics at infusions (Fig 2). Out of 1401 total CSF cultures, 64 (4.56%) were positive. The most common organism grown was Cutibacterium acnes, which typically grew in only broth culture (82%), suggesting low bacterial burden (Fig 3). The other 7 patients with positive cultures remained asymptomatic with no intervention required. [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: At our institution, we have found that in asymptomatic patients with frequently accessed ventricular reservoirs, positive CSF culture with low virulence skin flora was common, and rarely required intervention. This strategy reduced the risks of invasive surgery, prolonged antibiotic courses, and missed infusions. In the future, routine screening cultures in asymptomatic patients can be avoided. DISCLOSURES: Raymond Wang, MD, Biomarin Pharmaceutical: Advisor/Consultant|Biomarin Pharmaceutical: Grant/Research Support|Biomarin Pharmaceutical: equity interest Antonio C. Arrieta, MD, FIDSA, FPIDS, Astellas Pharma Global Development, Inc.: Advisor/Consultant|Astellas Pharma Global Development, Inc.: Grant/Research Support|Astellas Pharma Global Development, Inc.: Honoraria|Cumberland Pharmaceutical: Grant/Research Support|IDbyDNA: Advisor/Consultant|IDbyDNA: Grant/Research Support|Melinta: Grant/Research Support|Merck: Advisor/Consultant|Merck: Grant/Research Support|Nabriva: Grant/Research Support|Paratek Pharmaceuticals: Grant/Research Support|Pfizer, Inc: Advisor/Consultant|Pfizer, Inc: Grant/Research Support|Roche/Genentech: Grant/Research Support|The Medicine Company: Grant/Research Support
format Online
Article
Text
id pubmed-10677598
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106775982023-11-27 2438. Positive Cerebrospinal Fluid Cultures from Intraventricular Reservoirs for CLN2 Patients: One Institution's Experience Fote, Gianna Schafenacker, Amanda Sherlock, Daniel C So, Justin Himstead, Alexander Davies, Jordan Pedroza, Sarah Gornick, Wendi Wang, Raymond Olaya, Joffre Arrieta, Antonio C Singh, Jasjit Open Forum Infect Dis Abstract BACKGROUND: Enzyme replacement therapy (ERT) with cerliponase alfa (Brineura) has been shown to slow progression of milestone deterioration in Neuronal Ceroid Lipofuscinosis Type 2 (CLN2), an inherited neurodegenerative lysosomal storage disorder. Brineura must be administered intraventricularly every 2 weeks, necessitating the placement of ventricular reservoirs and requiring frequent access. Traditionally, positive cerebrospinal fluid (CSF) cultures are managed with device replacement and antibiotic treatment. We sought to establish which circumstances might allow for careful observation without device removal. In this study, we report our single-institution experience with clinical outcomes of positive CSF cultures in 16 CLN2 patients over 6 years. METHODS: We retrospectively reviewed a cohort of 16 patients with CLN2 disease who had ventricular reservoirs placed for ERT administration. At each ERT infusion, CSF was collected by sterile technique and cultured by both thioglycolate broth and agar plate. Epidemiologic and microbiologic data, symptomatology, total antibiotic days, removal and replacement of ventricular reservoir, hospital length of stay, and mortality were analyzed for each patient. RESULTS: In our cohort, 11 of 16 patients (69%) had at least one positive CSF culture (Fig 1). Of the 11 with positive cultures, only 3 had their device removed and replaced for a positive culture with concurrent antibiotic treatment at our center, and 2 patients subsequently have been treated with prophylactic antibiotics at infusions (Fig 2). Out of 1401 total CSF cultures, 64 (4.56%) were positive. The most common organism grown was Cutibacterium acnes, which typically grew in only broth culture (82%), suggesting low bacterial burden (Fig 3). The other 7 patients with positive cultures remained asymptomatic with no intervention required. [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: At our institution, we have found that in asymptomatic patients with frequently accessed ventricular reservoirs, positive CSF culture with low virulence skin flora was common, and rarely required intervention. This strategy reduced the risks of invasive surgery, prolonged antibiotic courses, and missed infusions. In the future, routine screening cultures in asymptomatic patients can be avoided. DISCLOSURES: Raymond Wang, MD, Biomarin Pharmaceutical: Advisor/Consultant|Biomarin Pharmaceutical: Grant/Research Support|Biomarin Pharmaceutical: equity interest Antonio C. Arrieta, MD, FIDSA, FPIDS, Astellas Pharma Global Development, Inc.: Advisor/Consultant|Astellas Pharma Global Development, Inc.: Grant/Research Support|Astellas Pharma Global Development, Inc.: Honoraria|Cumberland Pharmaceutical: Grant/Research Support|IDbyDNA: Advisor/Consultant|IDbyDNA: Grant/Research Support|Melinta: Grant/Research Support|Merck: Advisor/Consultant|Merck: Grant/Research Support|Nabriva: Grant/Research Support|Paratek Pharmaceuticals: Grant/Research Support|Pfizer, Inc: Advisor/Consultant|Pfizer, Inc: Grant/Research Support|Roche/Genentech: Grant/Research Support|The Medicine Company: Grant/Research Support Oxford University Press 2023-11-27 /pmc/articles/PMC10677598/ http://dx.doi.org/10.1093/ofid/ofad500.2057 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Fote, Gianna
Schafenacker, Amanda
Sherlock, Daniel C
So, Justin
Himstead, Alexander
Davies, Jordan
Pedroza, Sarah
Gornick, Wendi
Wang, Raymond
Olaya, Joffre
Arrieta, Antonio C
Singh, Jasjit
2438. Positive Cerebrospinal Fluid Cultures from Intraventricular Reservoirs for CLN2 Patients: One Institution's Experience
title 2438. Positive Cerebrospinal Fluid Cultures from Intraventricular Reservoirs for CLN2 Patients: One Institution's Experience
title_full 2438. Positive Cerebrospinal Fluid Cultures from Intraventricular Reservoirs for CLN2 Patients: One Institution's Experience
title_fullStr 2438. Positive Cerebrospinal Fluid Cultures from Intraventricular Reservoirs for CLN2 Patients: One Institution's Experience
title_full_unstemmed 2438. Positive Cerebrospinal Fluid Cultures from Intraventricular Reservoirs for CLN2 Patients: One Institution's Experience
title_short 2438. Positive Cerebrospinal Fluid Cultures from Intraventricular Reservoirs for CLN2 Patients: One Institution's Experience
title_sort 2438. positive cerebrospinal fluid cultures from intraventricular reservoirs for cln2 patients: one institution's experience
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677598/
http://dx.doi.org/10.1093/ofid/ofad500.2057
work_keys_str_mv AT fotegianna 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience
AT schafenackeramanda 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience
AT sherlockdanielc 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience
AT sojustin 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience
AT himsteadalexander 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience
AT daviesjordan 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience
AT pedrozasarah 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience
AT gornickwendi 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience
AT wangraymond 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience
AT olayajoffre 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience
AT arrietaantonioc 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience
AT singhjasjit 2438positivecerebrospinalfluidculturesfromintraventricularreservoirsforcln2patientsoneinstitutionsexperience